Vendor Intelligence Report: Elite Research USA

Published 3 Jul 2026. 26-page investigative report on who is behind Elite Research USA: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Elite Research USA is traceable but uneven. Across 50 Finnrick lab tests, Elite Research USA shows 23 pass / 27 fail, an overall pass rate of 46%. Retatrutide is the strongest aggregate signal, Tirzepatide sits above the portfolio average but is thinly sampled, while CJC-1295 and BPC-157 are poor Elite choices. Under stricter grading, ratings contract, so better products still need fresh batch verification.

The entity trail is more concrete than many peptide shops: a Wyoming LLC, Texas Comptroller record, named partners and a Seabrook PO Box. The unresolved issues are governance and transparency. Field checks found no Texas foreign-LLC registration, an X account self-identifies as a managing partner outside the Texas PIR, the current storefront is login-gated, and Janoshik public search returned zero Elite results.

Elite's growth is increasingly code-driven. The report maps a mid-2026 influencer expansion across X, Instagram, Facebook and Reddit, including paid-partnership and discount-code posts that sometimes mix research-use disclaimers with consumer outcome claims. Captured reviews also allege a DMAA/Enclomiphene mix-up and underdosed HCG; Finnrick did not test those parcels, but they remain label-control and support signals.

Inside the full report:

  • Product-specific Finnrick read, score-distribution chart and methodology-divergence analysis for all 7 tested products
  • Texas Comptroller PIR exhibits, taxpayer-number trail and unresolved Wyoming formation verification
  • Login-gated storefront captures, domain history, CloudFront/S3 infrastructure and archived payment-rail notes
  • Janoshik zero-result capture and COA-transparency assessment
  • Affiliate timeline with promoter codes, disclosure review and paid-partnership exhibits
  • Trustpilot incident exhibits for the DMAA/Enclomiphene and HCG allegations

Risk assessment

  • CJC-1295, BPC-157 and Mazdutide quality risk — high: Finnrick rates CJC-1295 17.54% with 1 pass / 9 fail, BPC-157 37.92% with 2 pass / 7 fail, and Mazdutide 43.72% with 0 pass / 3 fail; these are poor Elite choices.
  • Retatrutide lot-level identity risk — high: Retatrutide is Elite’s strongest aggregate product at 79.28% with 8 pass / 2 fail, but the supplied certificate trail reports one May 8, 2026 sample with 0.00% Retatrutide detected.
  • Fulfillment and label-control risk for Enclomiphene/HCG — high: Captured Trustpilot reviews allege DMAA was shipped instead of Enclomiphene and that HCG was severely underdosed; Finnrick did not independently test those parcels.
  • COA transparency and pre-purchase verification risk — high: The storefront is login-gated and Janoshik public search returned zero Elite Research USA results as of July 2, 2026, leaving weak public batch-verification signals.
  • Affiliate-promotion and disclosure risk — high: The affiliate scan found 11 promoter or mention sources, 9 with a code/link and only 2 clearly disclosed in the structured scan; field captures show rapid influencer expansion.
  • Operating-compliance and regulatory-disruption risk — medium: Elite is a Wyoming LLC using a Texas PO Box, field checks found no Texas foreign-LLC registration, and FDA PCAC review creates category-level disruption risk; no direct Elite enforcement was found.